B cell modulation by TLR9 and discovery of novel treatment in inflammatory bowel disease

• Project/Area Number: 22790657
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Gastroenterology
• Research Institution: Fukushima Medical University
• Principal Investigator: KATAKURA Kyoko 福島県立医科大学, 医学部, 講師 (70423788)
• Project Period (FY): 2010 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000); Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: 炎症性腸疾患 / Toll-like receptor / 制御性B細胞 / Toll-like recetor 9

Research Abstract

We investigated whether TLR9 agonist CpG DNA protects mice from colonic inflammation through activated plasmacytoid dedritic cells(pDCs) and B cell proliferation. Administration of CpG DNA significantly suppressed colonic inflammation of DSS-induced colitis, and we could detect production of regulatory cytokines in mesenteric lymph nodes. Although we could not detect regulatory B cells as well as its induction by co-cultured with CpG DNA stimulated pDC. These results suggest that B cells, especially regulatory B cells didn' t concerned to protective effect of CpG DNA to mouse DSS colitis.